SLCO2B1 and prostate cancer: In agreement, Hahn et al. [41] corroborated that patients heterozygous for SLCO2B1 rs12422149 with metastatic castration-resistant prostate cancer receiving first-line abiraterone acetate had improved progression-free survival as compared to homozygous wildtype carriers (GG) (Figure 1).